-
Goldman Initiates Impax Labs With Sell Rating, $33 Target
Monday, June 6, 2016 - 11:46am | 322Read More...Although Impax Laboratories Inc (NASDAQ: IPXL)'s prospects have improved since the remediation of its manufacturing issues in 2015, Goldman Sachs’ Stephan Stewart believes “the fundamental outlook is fully reflected in the stock,” and there could be “increased competition...
-
Biotie Therapies Surging Following IPO Debut
Thursday, June 11, 2015 - 4:18pm | 221Read More...Shares of Biotie Therapies Corp. (NASDAQ: BITI) traded higher by more than 39 percent in their public debut. The Finland-based firm is a specialized drug development company focused on products for neurodegenerative and psychiatric disorders. The company is developing a therapy to extend the...
-
Biotie Therapies Making Strides In Neurodegenerative Diseases
Wednesday, June 10, 2015 - 12:50pm | 887Read More...Finnish Biotech company Biotie Therapies (NASDAQ: BITI) (OTC: BIOZF) hopes to raise $56 million in its upcoming IPO this Friday, June 12. The company will offer 3.8 ADSs at price of $14.82, up 12 percent from its original offer. The deal was initially set for 3.4 million ADSs at the same price...
